| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/27/2005 | US20050019811 Neutral amino acid transporter and gene thereof |
| 01/27/2005 | US20050019754 Peptides of given sequence with immunogenic epitopes activating CD8+ class I major histocompatibility complex restricted cytotoxic T-lymphocytes for patients harboring latent HCMV infection in the absence of active viral replication; using enriched antigen presenting cells; vaccines |
| 01/27/2005 | US20050019752 Novel chimeric rev, tat, and nef antigens |
| 01/27/2005 | US20050019751 Contacting human scavenger receptor class B type I with polypeptide and measuring ability of test compound to inhibit binding; used in treatment and prophylaxis |
| 01/27/2005 | US20050019349 Poxvirus containing formulations and process for preparing stable poxvirus containing compositions |
| 01/27/2005 | US20050019348 Vaccine using genetic engineered virus; transformated Dna; induce immunology response; veterinary medicine |
| 01/27/2005 | US20050019347 Dna sequences and coding for hepatitis virus antigen |
| 01/27/2005 | US20050019344 Antigens; vaccines; isolated peptide |
| 01/27/2005 | US20050019343 administering an effective dose of a polypeptide comprising an immunogenic fragment of A beta (SEQ ID NO:1) and an adjuvant in a regime effective to induce an immune response comprising antibodies to the A beta fragment; Alzheimer's disease |
| 01/27/2005 | US20050019342 Mixture cancer immunotherapy and adjuvant; anticancer agents |
| 01/27/2005 | US20050019341 Gene that codes tumor antigen is detected by cytotoxic lymphocyte; isolated from Dna libraries |
| 01/27/2005 | US20050019340 Oil in water emulsion; immunology response; using cancer antigen |
| 01/27/2005 | US20050019339 Forming antibodies that recognize epitopes in nature protein; antigen encapsulated in liposomes |
| 01/27/2005 | US20050019337 Immunization method against Neisseria meningitidis serogroups A and C |
| 01/27/2005 | US20050019336 Human prostate cell lines in cancer treatment |
| 01/27/2005 | US20050019335 Attenuated mutant Salmonella bacteria containing deactivated gene used as vaccine |
| 01/27/2005 | US20050019334 Interleukin antibody or fusion protein; comprising active material and FC domain; Escherichia coli cells |
| 01/27/2005 | US20050019330 administering an antibody that specifically binds to the amyloid deposit or a component thereof; can be a human, humanized, chimeric or nonhuman antibody and can be monoclonal or polyclonal; also a novel monoclonal antibody which specifically binds to an epitope within residues 13-28 of A beta |
| 01/27/2005 | US20050019329 Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tPA) and tPA inhibitors useful therein |
| 01/27/2005 | US20050019328 Prevention and treatment of amyloidogenic disease |
| 01/27/2005 | US20050019326 Antiinflammatory agents; tissue injury; autoimmune disease; anticancer agents |
| 01/27/2005 | US20050019324 Peptides and antibodies to muc 1 proteins |
| 01/27/2005 | US20050019322 Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| 01/27/2005 | US20050019321 Method of obtaining protection against bystander allergen |
| 01/27/2005 | US20050019305 Inhibiting ligand/receptor interactions involving immunoglobulins, interleukins, interferon-alpha, histamine and/or leukotrienes; long term relief; kits |
| 01/27/2005 | US20050019304 Novel human mage-like protein |
| 01/27/2005 | CA2805464A1 Human antibody molecules for il-13 |
| 01/27/2005 | CA2804901A1 Human antibody molecules for il-13 |
| 01/27/2005 | CA2537896A1 East coast fever vaccine based on ctl-specific schizont antigens |
| 01/27/2005 | CA2532781A1 The anti-platelet membrane glycoprotein vi monoclonal antibody |
| 01/27/2005 | CA2532595A1 Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin |
| 01/27/2005 | CA2532323A1 Antibodies to cd44 vra and methods of use |
| 01/27/2005 | CA2532164A1 Subunit vaccine against respiratory syncytial virus infection |
| 01/27/2005 | CA2532127A1 Regulatory t-cells containing galectins for the therapy and diagnosis of diseases |
| 01/27/2005 | CA2531393A1 Recombinant expression of streptococcus pyogenes cysteine protease and immunogenic compositions thereof |
| 01/27/2005 | CA2527878A1 Antibodies and fusion proteins that include engineered constant regions |
| 01/27/2005 | CA2525825A1 Hiv polynucleotides and polypeptides derived from botswana mj4 |
| 01/26/2005 | EP1500702A1 APO-2LI and APO-3 apoptosis polypeptides from the TNFR1 familiy |
| 01/26/2005 | EP1500665A1 METHOD FOR CONSTRUCTING scDb LIBRARIES |
| 01/26/2005 | EP1500663A1 Secreted proteins and their uses |
| 01/26/2005 | EP1500431A2 Immobilised affinity medium and its use in separation |
| 01/26/2005 | EP1500402A1 Cell death inhibitor |
| 01/26/2005 | EP1500400A1 Drug containing antibody composition |
| 01/26/2005 | EP1500399A1 Active or passive immunization against proapoptotic neurotrophins for the treatment or prevention of neurodegenerative deseases |
| 01/26/2005 | EP1500329A2 Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| 01/26/2005 | EP1499886A1 Methods and compositions for inducing an immune response |
| 01/26/2005 | EP1499735A2 Optimization of transgene expression in mammalian cells |
| 01/26/2005 | EP1499730A1 Immunoconjugates for the treatment of tumours |
| 01/26/2005 | EP1499729A1 Derivatives of the nf-kappab inducing enzyme, their preparation and use |
| 01/26/2005 | EP1499726A1 Chimeric camp factors for vaccination against streptococcus infection |
| 01/26/2005 | EP1499724A1 Derivatives of the il-2 receptor gamma chain, their production and use |
| 01/26/2005 | EP1499634A2 COMBINATION VACCINES INCLUDING IMMUNOGENIC GapC AND CAMP FACTOR POLYPEPTIDES |
| 01/26/2005 | EP1499630A2 Streptavidin expressed gene fusions and methods of use thereof |
| 01/26/2005 | EP1499392A1 Method and agents for the prevention, inhibition, and therapy of cancers |
| 01/26/2005 | EP1499358A1 Ph-sensitive polymer |
| 01/26/2005 | EP1499355A2 Use of parapox b2l protein to treat cancer and modify immune responses |
| 01/26/2005 | EP1499354A2 Methods of using cytokine antagonists to treat hiv infection and aids |
| 01/26/2005 | EP1499353A2 Antibodies that specifically bind to tl5 |
| 01/26/2005 | EP1499352A1 Recombinant anti-interleukin-9 antibodies |
| 01/26/2005 | EP1499351A2 Antibodies that specifically bind to tr2 |
| 01/26/2005 | EP1499350A2 Nucleic acid and corresponding protein entitled 205p1b5 useful in treatment and detection of cancer |
| 01/26/2005 | EP1499349A2 Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen |
| 01/26/2005 | EP1499348A2 Multi plasmid system for the production of influenza virus |
| 01/26/2005 | EP1499346A2 Treatment of type 1 diabetes before and after expression of predisposition markers |
| 01/26/2005 | EP1499327A2 Beta -amyloid peptide-binding proteins and polynucleotides encoding the same |
| 01/26/2005 | EP1499191A1 Regulated attenuation of live vaccines to enhance cross protective immunogenicity |
| 01/26/2005 | EP1499187A2 Immunostimulatory g,u-containing oligoribonucleotides |
| 01/26/2005 | EP1330237B1 Delivery system for entrapping charged macromolecules and a method for preparing same |
| 01/26/2005 | EP1231926B1 Biomolecular complex formed between hyaluronic acid and a biomolecule, its method of manufacture and medical uses thereof |
| 01/26/2005 | EP1129723B1 Combined vaccine against both hav and measle virus and method of producing it |
| 01/26/2005 | EP1127133B1 Polypeptide mediating cell permeability |
| 01/26/2005 | EP1061950B1 Live vaccine for human immunodeficiency virus |
| 01/26/2005 | EP1058558B1 Adjuvated, live recombinant vaccines against influenza- and herpesviruse |
| 01/26/2005 | EP1015595B1 Peptides derived from the attachment (g) protein of respiratory syncytial virus |
| 01/26/2005 | EP0996636B1 The ha-1 antigen |
| 01/26/2005 | EP0934412B1 HUMAN THYMOSIN beta 15 GENE, PROTEIN AND USES THEREOF |
| 01/26/2005 | EP0871486B1 Diphtheria toxin epitopes |
| 01/26/2005 | EP0793717B1 Oral immunization with transgenic plants |
| 01/26/2005 | EP0791063B1 Carrier protein having an adjuvant effect, immunogenic complex containing same, preparation method therefor, nucleotide sequence and vaccine |
| 01/26/2005 | EP0769968B1 Retroviral vectors produced by producer cell lines resistant to lysis by human serum |
| 01/26/2005 | EP0652953B1 Morphogenic protein soluble complex and composition thereof |
| 01/26/2005 | EP0579758B1 Parathyroid hormone receptor and dna encoding same |
| 01/26/2005 | CN1571836A Human antibodies specific for interleukin 15 (IL-15) |
| 01/26/2005 | CN1571834A Cell therapy method for the treatment of tumors |
| 01/26/2005 | CN1571677A Hookworm vaccine |
| 01/26/2005 | CN1571633A Mycoplasma bovis challenge model and methods for administering M.bovis and methods for inducing pneumonic lung lesions |
| 01/26/2005 | CN1570115A Optimized SARS coronary virus spike protein gene |
| 01/26/2005 | CN1570114A Nucleotide specific for bacillus coli O167 type and Sh.boydii 3 type O-antigen |
| 01/26/2005 | CN1570113A Nucleotide specific for bacillus coli O125 type O-antigen |
| 01/26/2005 | CN1570109A Production method of trangenic plant for expressing hepatitis B virus envelop protein and its products |
| 01/26/2005 | CN1570101A Optimized SARS coronary virus N protein gene |
| 01/26/2005 | CN1569900A Heavy chain variable region single domain antibody reinforced fusion protein VH-LDP-AE |
| 01/26/2005 | CN1569899A Recombinant nerve putrescence virus protein vaccine and its coding sequence and uses |
| 01/26/2005 | CN1569896A Preparation of composite specific yelk antibody igy against cutaneous infection and its use in treatment of cutaneous infection |
| 01/26/2005 | CN1569895A Yelk antibody specific for preventing pigling diarrhea and its preparing method and application |
| 01/26/2005 | CN1569893A Antigen epitope of gold staphylococcus virulence factor regulatory protein and its mimic epitope and use thereof |
| 01/26/2005 | CN1569880A SEA mutant gene and use for fusion protein thereof with ScFv gene |
| 01/26/2005 | CN1569231A Specific antibody IgY immune preparation and its application in the prevention and treatment of mycobacterium tuberculosis infection |
| 01/26/2005 | CN1569230A Preparation and application of a gene engineering vaccine of muscle growth retarder |
| 01/26/2005 | CN1569229A IgY product for resisting mouth and upper respiratory tract infection and its application |